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Summary In breast cancer, inactivating point mutations in the E-cadherin gene are frequently found in invasive lobular carcinoma (ILC) but
never in invasive ductal carcinoma (IDC). Lobular carcinoma in situ (LCIS) adjacent to ILC has previously been shown to lack E-cadherin
expression, but whether LCIS without adjacent invasive carcinoma also lacks E-cadherin expression and whetherthe gene mutations present
in ILC are already present in LCIS is not known. We report here that E-cadherin expression is absent in six cases of LCIS and present in 150
cases of ductal carcinoma in situ (DCIS), both without an adjacent invasive component. Furthermore, using mutation analysis, we could
demonstrate the presence of the same truncating mutations and loss of heterozygosity (LOH) of the wild-type E-cadherin in the LCIS
component and in the adjacent ILC. Our results indicate that E-cadherin is a very early target gene in lobular breast carcinogenesis and plays
a tumour-suppressive role, additional to the previously suggested invasion-suppressive role.
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The E-cadherin gene is located on chromosome band 16q22.1 and
encodes a calcium-dependent cellular adhesion molecule crucial
for epithelial organization and adhesion (Takeichi, 1991).
In breast carcinoma, reduced expression ofE-cadherin has been
found in 50% ofinvasive ductal carcinoma (IDC). In most cases of
invasive lobular carcinoma (ILC), however, a complete loss of
expression has been observed (Gamallo et al, 1993; Moll et al,
1993; Rasbridge et al, 1993; Berx et al, 1995). Mutations in the
E-cadherin gene have been found previously in invasive lobular
breast carcinomas (Kanai et al, 1994; Berx et al, 1995). We have
shown that E-cadherin gene mutations and loss of the wild-type
allele by loss ofheterozygosity (LOH) is the predominant mecha-
nism by which E-cadherin protein expression is lost (Berx et al,
1995, 1996). These results indicate that E-cadherin acts as a clas-
sical tumour-suppressor gene. Recently, we and others found loss
of immunohistochemical E-cadherin expression in lobular carci-
noma in situ (LCIS), adjacent to ILC (Moll et al, 1993). This is
surprising as, on the basis ofthe in vitro experiments (Frixen et al,
1991; Vleminckx et al, 1991), E-cadherin inactivation would be
expected to play a role in the transition of in situ carcinoma to
invasive carcinoma or even metastatic cancer.
In this study we have investigated the expression ofE-cadherin
in six cases ofLCIS and forcomparison also in 150 cases ofductal
carcinoma in situ (DCIS), both without an invasive component. In
addition, we have performed mutation analysis on the microdis-
sected LCIS component adjacent to invasive lobular carcinoma of
two cases with known E-cadherin mutations. For these two
tumours and for six cases of LCIS without invasion, LOH was
studied on 16q22.1, where the E-cadherin gene is located.
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MATERIALS AND METHODS
Tumours
We collected 156 paraffin-embedded cases of pure in situ carci-
noma, of which 150 were classified as DCIS and six as LCIS. In
addition, we selected two tumours from a series of 26 ILC with
known E-cadherin mutations (Berx et al, 1996) on the basis of an
extensive LCIS component allowing microdissection. In case
BT554, the E-cadherin gene showed a G > T transition in exon 10,
codon 504; in case BT995, a deletion ofG at exon 9, codon 408 was
found. Both mutations are expected to lead to a truncated protein.
Immunohistochemistry
Immunohistochemical staining was performed after antigen
retrieval using the anti-E-cadherin monoclonal antibody (HECD-1,
dilution 1:500, Takara Biomedicals, Shuzo, Japan) that recognizes
an extracellular epitope on human E-cadherin (Berx et al, 1995).
To ensure a proper discrimination of the in situ component, a
consecutive section was stained with an antibody recognizing the
myoepithelial layer [smooth muscle antigen (SMA) clone ASMI,
1:500, no pretreatment, Progen].
DNA extraction
Microdissection was performed on four 12-pm deparaffinized
haematoxylin and eosin (H and E)-stained sections. From the same
block, a 5-gm H and E-stained section was used for orientation. In
both cases, DNA was extracted from the ILC and LCIS compo-
nents as described by Isola et al (1994). In addition, in case BT995,
DNA was extracted from an intraductal proliferation, which
was classified as atypical ductal hyperplasia (ADH). Constitutive
DNA was extracted from peripheral blood lymphocytes. After
microdissection of the tumour cells, DNA was extracted from
1131ADH
E-cadherin
ILC
E-cadherin
Figure 1 Immunohistochemical staining with an antibody directed to E-cadherin in lobular invasive carcinoma and adjacent LCIS and ADH. The specific
plasma membrane staining of E-cadherin is visible in the normal ducts and the epithelial cells of ADH. No membrane-associated expression of E-cadherin is
observed in the invasive and in the LCIS component, only faint cytoplasmic staining is present. The marked areas (D, ADH; L, LCIS; 1, invasive) were
microdissected for DNA isolation
paraffin-embedded material of six LCIS cases without an adjacent
invasive component.
Loss of heterozygosity and DNA sequence analysis
LOH analysis was performed on each of the three tumour compo-
nents and on six cases ofLCIS without an invasive component with
six polymorphic microsatellite markers: D16S318, D16S503 prox-
imal to the E-cadherin gene, D16S512, D16S752, D16S2624 distal
to the E-cadherin gene and D16S305 located on 16q24.3.
Quantification ofthe allele intensities was performed on aMolecular
Dynamics Phosphor Imager. E-cadherin sequences harbouring the
mutation were amplified by polymerase chain reaction (PCR) using
the following primers: BT 554 5'-TGGATGTGCTGGATGTGAAT-
3' (forward) and 5'-TCCATAAATGTGTCTGGCTCC-3' (reverse),
nucleotide position 1518 to 1537 and 1626 to 1648, and BT995
5'-CT'TITGCTCTGCAGTACAAGGG-3' (forward) and 5'-CCAC-
CATCATCATTCAATATGG-3' (reverse), nucleotide position 1220
to 1238 and 1335 to 1358. Nucleotide positions correspond to the
E-cadherin sequence deposited in the EMBL/GenBank database
libraries (accession no. Z13009). PCR buffer and Super Taq
polymerase were obtained from HT Biotechnology, Cambridge,
UK. Amplified DNA fragments were sequenced with an internal
primer (BT554 5'-ATGAAGCCCCCATCTlTTGTG-3' and BT995
5'-CTGAGAACGAGGCTAACGTC-3') in a double-stranded cycle
sequence system (Perkin Elmer) and analysed on a 6% polyacry-
lamide gel.
RESULTS
All 150 cases of DCIS studied showed clear plasma membrane-
associated E-cadherin expression. In 11% ofthe cases staining was
reduced compared with normal epithelium. In all six cases of
LCIS, E-cadherin expression was completely absent in the tumour
cells; the presence of E-cadherin staining in normal ductal epithe-
lial cells served as an internal positive control.
In the two invasive lobular carcinomas with known mutations in
the E-cadherin gene (BT554 and BT995), immunohistochemical
expression was absent in the invasive as well as in the LCIS compo-
nent, but present in the ADH component. (Figure 1). The SMA
staining revealed a positive staining of the myoepithelial layer
around the ducts containing the in situ component, which indicates
the presence of an intact basement membrane surrounding the in
situ component (not shown). DNA sequence analysis of the
microdissected LCIS components revealed the presence of the
same mutations as in the ILC, whereas in the ADH component only
the wild-type sequence could be identified (Figure 2). LOH
analysis showed loss of the same alleles with markers on 16q22.1
in both the LCIS and the invasive component. LOH on 16q22.1 was
absent in the ADH component. With marker D16S752, four of the
five informative LCIS cases showed LOH (Figure 3).
DISCUSSION
Our results show that E-cadherin is inactivated in not only invasive
lobular carcinoma and LCIS adjacent to ILC but also in LCIS
without an invasive component. In 150 cases of DCIS without an
invasive component, E-cadherin expression was present. This
supports the emerging evidence that E-cadherin is specifically
associated with the lobular phenotype ofbreast cancer (Moll et al,
1993; Berx et al, 1995, 1996). We hypothesize that E-cadherin
inactivation plays a crucial role in the dispersed growth pattern
in both LCIS and ILC.
In the six cases of LCIS without an adjacent invasive compo-
nent, no expression ofE-cadherin was found and LOH on 16q22.1
could be detected in four out of five informative cases. This and
the finding of identical mutations and LOH for the same markers
in the paired invasive and in situ components indicates that inacti-
vation of E-cadherin can occur according to the two-hit Knudson
model and that it may underlay the formation ofthe in situ compo-
nent and precede progression to an invasive tumour.
On the basis of in vitro experiments (Vleminckx et al, 1991),
inactivation of E-cadherin was hypothesized to be involved in the
acquisition of an invasive tumour type. However, in this study, we
show that in the development oflobular breast carcinoma inactiva-
tion of E-cadherin occurs at a very early stage and is already
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Figure 2 Example of mutation analysis of the E-cadherin gene in human lobular breast carcinoma and theiradjacent lobular and ADH component. In BT995,
aone-basepair deletion occurred in the tumour(arrow). F, DNA from frozen tumourmaterial; P, DNA from paraffin-embedded tissue
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Figure3 LOH at the cadherin locus with marker 6S752 in six cases of
LCIS without an invasive component. In the lanes marked with*, clear loss of
one allele is visible in the lane containing tumour DNA (T) compared with the
lane containing normal DNA (N)
present in LCIS without invasion and LCIS adjacent to an invasive
component. In DCIS, we have never observed complete loss of
E-cadherin expression; we did however find reduced expression in
11% of the DCIS cases. Down-regulation of E-cadherin can also
occur by hypermethylation of the promoter region of E-cadherin
and may lead to altered tumour cell behaviour, although this is not
restricted to a distinct tumour type (Graff etal, 1995; Yoshiura
et al, 1995). As complete loss of E-cadherin expression is never
observed in DCIS, inactivating E-cadherin mutations can not be
present in DCIS, indicating different genetic pathways for the
development of LCIS and DCIS. Our results indicate that
E-cadherin is a classical tumour-suppressor gene and a very
early target in lobular breast carcinogenesis and plays a tumour-
suppressive role additional to the previously suggested invasion-
suppressive role (Vleminckx et al, 1991).
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